Armata reports FDA submissions complete ahead of AP-SA02 Phase 3

Armata Pharmaceuticals announced on July 20, 2026 that it has completed a series of clinical, regulatory, and manufacturing milestones supporting the planned advancement of AP-SA02 toward a Phase 3 study, according to an 8-K filing. AP-SA02 is a fixed multi-phage cocktail being developed for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive or methicillin-resistant S. aureus.¹

The company said it submitted the complete Phase 3 superiority protocol to the FDA for AP-SA02, incorporating all comments received in the End-of-Phase 2 meeting written response.¹ It also submitted complete responses to all FDA comments on clinical, Chemistry, Manufacturing, and Controls, and regulatory topics raised in the EOP2 meeting written response.¹

On the manufacturing side, Armata completed four engineering runs of AP-SA02 at its in-house cGMP manufacturing facility in Los Angeles, with production of clinical trial material as the next planned manufacturing step.¹ The Phase 3 study remains anticipated to initiate in the second half of 2026.¹

On funding, Armata noted a $2.5 million award announced June 23, 2026, a continuation of a previous Department of Defense award, bringing total funding under that award to $28.7 million.¹ The company said it is in close communication with the DoD regarding potential new support and continues to pursue other funding pathways for the Phase 3 study.¹

In a leadership update, Armata announced that David House was promoted to Chief Financial Officer, having served as Senior Vice President, Finance and Principal Financial Officer since August 2024.¹ The prior Phase 2a diSArm study results were highlighted in a late-breaking oral presentation at IDWeek 2025 in October 2025.¹